Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golcadomide plus rituximab versus investigator's choice in relapsed or refractory follicular lymphoma
NL-OMON60343Phase 3Recruiting
- Sponsor
- Celgene Corporation
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of golcadomide and rituximab in follicular lymphoma (FL) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Progression-free survival by independent review. Started Sep 2025; status: recruiting.
02
Drugs
golcadomiderituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NL-OMON60343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60343.